Previous 10 | Next 10 |
home / stock / biib / biib articles
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this artic...
Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 3.19% on an annualized basis producing an average annual return of 10.72...
The S&P 500 Index has risen by 19% year-to-date, with three weeks remaining in the year and just a five percentage point gap from the all-time ...
In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess c...
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a rene...
Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.35% on an annualized basis producing an average annual return of 9.84%...
In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehe...
Biogen Inc (NASDAQ: BIIB) reported better-than-expected third-quarter earnings. Biogen posted quarterly sales of $2.53 billion, beating the consen...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...